First Manhattan’s Bio-Rad Laboratories Class A BIO Stock Holding History

First Manhattan’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,915	Closed	-$580K	–	756
2025 Q4	$580K	Sell	1,915 -200	-9%	-$62.4K	﹤0.01%	528
2025 Q3	$593K	Sell	2,115 -1,950	-48%	-$531K	﹤0.01%	512
2025 Q2	$981K	Sell	4,065 -40	-1%	-$9.46K	﹤0.01%	424
2025 Q1	$1,000K	Sell	4,105 -600	-13%	-$181K	﹤0.01%	392
2024 Q4	$1.55M	Sell	4,705 -870	-16%	-$295K	﹤0.01%	332
2024 Q3	$1.87M	Sell	5,575 -525	-9%	-$167K	0.01%	300
2024 Q2	$1.67M	Sell	6,100 -1,610	-21%	-$468K	0.01%	308
2024 Q1	$2.67M	Sell	7,710 -741	-9%	-$244K	0.01%	267
2023 Q4	$2.73M	Sell	8,451 -72,925	-90%	-$22.9M	0.01%	263
2023 Q3	$26.9M	Buy	+81,376	New	+$31.4M	0.1%	85
2023 Q1	–	Sell	-13	Closed	-$5.47K	–	1546
2022 Q4	$5.47K	Buy	+13	New	+$5.25K	﹤0.01%	1373
2022 Q3	–	Sell	-250	Closed	-$123K	–	1518
2022 Q2	$123K	Hold	250	–	–	﹤0.01%	801
2022 Q1	$140K	Hold	250	–	–	﹤0.01%	819
2021 Q4	$188K	Hold	250	–	–	﹤0.01%	754
2021 Q3	$186K	Hold	250	–	–	﹤0.01%	754
2021 Q2	$161K	Hold	250	–	–	﹤0.01%	774
2021 Q1	$142K	Hold	250	–	–	﹤0.01%	769
2020 Q4	$145K	Hold	250	–	–	﹤0.01%	727
2020 Q3	$128K	Hold	250	–	–	﹤0.01%	726
2020 Q2	$112K	Hold	250	–	–	﹤0.01%	748
2020 Q1	$87K	Hold	250	–	–	﹤0.01%	764
2019 Q4	$92K	Hold	250	–	–	﹤0.01%	803
2019 Q3	$83K	Sell	250 -349	-58%	-$114K	﹤0.01%	825
2019 Q2	$187K	Hold	599	–	–	﹤0.01%	717
2019 Q1	$183K	Hold	599	–	–	﹤0.01%	729
2018 Q4	$139K	Hold	599	–	–	﹤0.01%	744
2018 Q3	$187K	Hold	599	–	–	﹤0.01%	735
2018 Q2	$172K	Hold	599	–	–	﹤0.01%	724
2018 Q1	$149K	Hold	599	–	–	﹤0.01%	726
2017 Q4	$142K	Hold	599	–	–	﹤0.01%	786
2017 Q3	$133K	Buy	599 +250	+72%	+$56.3K	﹤0.01%	752
2017 Q2	$78K	Hold	349	–	–	﹤0.01%	850
2017 Q1	$69K	Hold	349	–	–	﹤0.01%	872
2016 Q4	$63K	Hold	349	–	–	﹤0.01%	884
2016 Q3	$57K	Hold	349	–	–	﹤0.01%	894
2016 Q2	$49K	Hold	349	–	–	﹤0.01%	951
2016 Q1	$47K	Hold	349	–	–	﹤0.01%	925
2015 Q4	$48K	Hold	349	–	–	﹤0.01%	948
2015 Q3	$46K	Hold	349	–	–	﹤0.01%	956
2015 Q2	$52K	Sell	349 -119	-25%	-$17K	﹤0.01%	953
2015 Q1	$63K	Hold	468	–	–	﹤0.01%	924
2014 Q4	$56K	Buy	+468	New	+$53.9K	﹤0.01%	960

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

First Manhattan's BIO Position: Q1 2026 in Review

First Manhattan sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 1,915 shares — an estimated $580K sold.

First Manhattan first reported a position in BIO in Q4 2014 and held it in 42 quarters. The position peaked at $26.9M in Q3 2023. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

First Manhattan reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
First Manhattan sold 1,915 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $580K.
First Manhattan first reported a position in Bio-Rad Laboratories Class A in Q4 2014 and held it in 42 quarters.
First Manhattan's Bio-Rad Laboratories Class A position peaked at $26.9M in Q3 2023.
391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.